Cogent Biosciences Reports Recent Business Highlights and Second Quarter 2025 Financial Results
Cogent Biosciences (NASDAQ: COGT) reported significant achievements in Q2 2025, highlighted by positive top-line results from the SUMMIT trial evaluating bezuclastinib in NonAdvanced Systemic Mastocytosis. The trial met its primary endpoint with a statistically significant improvement in Total Symptom Score (24.3-point reduction vs. 15.4 points for placebo, p=0.0002).
The company strengthened its financial position through two major transactions: a $400 million debt facility with SLR Capital Partners and an upsized $230 million public offering. With $453 million in pro-forma cash, Cogent is funded through anticipated launch and into 2027. Q2 2025 resulted in a net loss of $73.5 million, with R&D expenses of $62.2 million.
Key upcoming catalysts include pivotal trial results from PEAK (GIST) and APEX (AdvSM) trials in 2H 2025, followed by the company's first NDA submission by year-end.
Cogent Biosciences (NASDAQ: COGT) ha riportato risultati significativi nel secondo trimestre del 2025, evidenziati dai risultati positivi della sperimentazione SUMMIT che valuta bezuclastinib nella Mastocitosi Sistemica Non Avanzata. Lo studio ha raggiunto l'endpoint primario con un miglioramento statisticamente significativo del punteggio totale dei sintomi (riduzione di 24,3 punti contro 15,4 punti per il placebo, p=0,0002).
L'azienda ha rafforzato la propria posizione finanziaria attraverso due operazioni importanti: una linea di credito da 400 milioni di dollari con SLR Capital Partners e un offerta pubblica aumentata a 230 milioni di dollari. Con 453 milioni di dollari in cassa pro-forma, Cogent 猫 finanziata fino al lancio previsto e oltre, fino al 2027. Il secondo trimestre del 2025 si 猫 chiuso con una perdita netta di 73,5 milioni di dollari, con spese di R&S pari a 62,2 milioni di dollari.
I principali eventi attesi includono i risultati degli studi fondamentali PEAK (GIST) e APEX (AdvSM) nella seconda met脿 del 2025, seguiti dalla prima presentazione NDA dell'azienda entro fine anno.
Cogent Biosciences (NASDAQ: COGT) report贸 logros significativos en el segundo trimestre de 2025, destacando resultados positivos principales del ensayo SUMMIT que eval煤a bezuclastinib en Mastocitosis Sist茅mica No Avanzada. El ensayo cumpli贸 su objetivo primario con una mejora estad铆sticamente significativa en la puntuaci贸n total de s铆ntomas (reducci贸n de 24.3 puntos frente a 15.4 puntos para placebo, p=0.0002).
La compa帽铆a fortaleci贸 su posici贸n financiera mediante dos transacciones importantes: una l铆nea de deuda de 400 millones de d贸lares con SLR Capital Partners y una oferta p煤blica ampliada de 230 millones de d贸lares. Con 453 millones de d贸lares en efectivo pro forma, Cogent est谩 financiada hasta el lanzamiento previsto y hasta 2027. El segundo trimestre de 2025 result贸 en una p茅rdida neta de 73.5 millones de d贸lares, con gastos en I+D de 62.2 millones de d贸lares.
Los principales catalizadores futuros incluyen resultados de ensayos clave de PEAK (GIST) y APEX (AdvSM) en la segunda mitad de 2025, seguidos por la primera presentaci贸n de NDA de la compa帽铆a antes de fin de a帽o.
Cogent Biosciences (NASDAQ: COGT)電� 2025雲� 2攵勱赴鞐� 欷戩殧頃� 靹标臣毳� 氤搓碃頄堨溂氅�, 牍勳頄夓劚 鞝勳嫚 牍勲靹疙彫歃�(Non-Advanced Systemic Mastocytosis)鞐愳劀 bezuclastinib鞚� 韽夑皜頃� SUMMIT 鞛勳儊鞁滍棙鞚� 旮嶌爼鞝侅澑 欤检殧 瓴瓣臣臧� 臧曥“霅橃棃鞀惦媹雼�. 鞚� 鞛勳儊鞁滍棙鞚� 齑� 歃濎儊 鞝愳垬(Total Symptom Score)鞚� 韱店硠鞝侅溂搿� 鞙犾潣氙疙暅 臧滌劆鞚� 欤茧悳 氇╉憸搿� 雼劚頃橃榾鞙茧┌(頂岆澕鞁滊炒 雽�牍� 24.3鞝� 臧愳唽 vs. 15.4鞝�, p=0.0002) 靹标车頃橃榾鞀惦媹雼�.
須岇偓電� SLR Capital Partners鞕�鞚� 4鞏� 雼煬 攵�毂� 鞁滌劋瓿� 2鞏� 3觳滊 雼煬 攴滊搿� 頇曤寑霅� 瓿店皽 氇 霊� 臧�歆� 欤检殧 瓯半灅毳� 韱淀暣 鞛 靸來儨毳� 臧曧檾頄堨姷雼堧嫟. 頂勲韽ゴ毵� 旮办 4鞏� 5,300毵� 雼煬鞚� 順勱笀鞚� 氤挫湢頃� Cogent鞚� 鞓堨爼霅� 於滌嫓旯岇 攴鸽Μ瓿� 2027雲勱箤歆� 鞛愱笀鞚� 頇曤炒霅� 靸來儨鞛呺媹雼�. 2025雲� 2攵勱赴電� 7,350毵� 雼煬鞚� 靾滌啇鞁�鞚� 旮半頄堨溂氅�, 鞐瓣惮臧滊皽 牍勳毄鞚� 6,220毵� 雼煬鞓�鞀惦媹雼�.
鞎烄溂搿滌潣 欤检殧 齑夒Г鞝滊電� 2025雲� 頃橂皹旮办棎 鞓堨爼霅� PEAK (GIST) 氚� APEX (AdvSM) 鞛勳儊鞁滍棙鞚� 欷戨寑頃� 瓴瓣臣鞕� 鞐半旯岇 須岇偓鞚� 觳� NDA 鞝滌稖鞚� 韽暔霅╇媹雼�.
Cogent Biosciences (NASDAQ : COGT) a annonc茅 des r茅sultats significatifs au deuxi猫me trimestre 2025, notamment des r茅sultats positifs de l'essai SUMMIT 茅valuant le bezuclastinib dans la mastocytose syst茅mique non avanc茅e. L'essai a atteint son crit猫re principal avec une am茅lioration statistiquement significative du score total des sympt么mes (r茅duction de 24,3 points contre 15,4 points pour le placebo, p=0,0002).
L'entreprise a renforc茅 sa position financi猫re gr芒ce 脿 deux op茅rations majeures : une facilit茅 de dette de 400 millions de dollars avec SLR Capital Partners et une offre publique augment茅e 脿 230 millions de dollars. Avec 453 millions de dollars en tr茅sorerie pro forma, Cogent est financ茅e jusqu'au lancement pr茅vu et jusqu'en 2027. Le deuxi猫me trimestre 2025 s'est sold茅 par une perte nette de 73,5 millions de dollars, avec des d茅penses de R&D de 62,2 millions de dollars.
Les catalyseurs cl茅s 脿 venir incluent les r茅sultats des essais pivots PEAK (GIST) et APEX (AdvSM) au second semestre 2025, suivis par la premi猫re soumission de NDA de l'entreprise d'ici la fin de l'ann茅e.
Cogent Biosciences (NASDAQ: COGT) meldete bedeutende Erfolge im zweiten Quartal 2025, insbesondere positive Ergebnisse der SUMMIT-Studie zur Bewertung von Bezuclastinib bei nicht-weiter fortgeschrittener systemischer Mastozytose. Die Studie erreichte ihren prim盲ren Endpunkt mit einer statistisch signifikanten Verbesserung des Gesamtsymptom-Scores (24,3-Punkte-Reduktion gegen眉ber 15,4 Punkten beim Placebo, p=0,0002).
Das Unternehmen st盲rkte seine finanzielle Lage durch zwei wesentliche Transaktionen: eine 400-惭颈濒濒颈辞苍别苍-顿辞濒濒补谤-顿补谤濒别丑别苍蝉蹿补锄颈濒颈迟盲迟 mit SLR Capital Partners und ein erh枚htes 枚ffentliches Angebot von 230 Millionen Dollar. Mit 453 Millionen Dollar an Pro-forma-Barmitteln ist Cogent bis zum erwarteten Markteintritt und bis ins Jahr 2027 finanziert. Das zweite Quartal 2025 schloss mit einem Nettoverlust von 73,5 Millionen Dollar ab, wobei die F&E-Ausgaben 62,2 Millionen Dollar betrugen.
Wichtige bevorstehende Meilensteine sind die entscheidenden Studienergebnisse der PEAK (GIST) und APEX (AdvSM)-Studien in der zweiten Jahresh盲lfte 2025, gefolgt von der ersten NDA-Einreichung des Unternehmens bis Jahresende.
- SUMMIT trial achieved statistical significance across all primary and secondary endpoints in NonAdvSM
- 87.4% of bezuclastinib-treated patients showed 鈮�50% reduction in serum tryptase vs 0% in control arm
- Secured $400M debt facility and raised $230M through public offering, with $453M pro-forma cash runway into 2027
- Favorable safety profile with majority of adverse events being low grade
- On track for first NDA submission by end of 2025 with potential commercial launch in 2026
- Increased net loss to $73.5M in Q2 2025 from $59.0M in Q2 2024
- R&D expenses increased to $62.2M from $54.3M year-over-year
- 5.9% discontinuation rate in SUMMIT trial due to ALT/AST elevations
- Significant dilution from 25.5M share public offering
Insights
Cogent's bezuclastinib shows impressive efficacy in NonAdvSM with strong statistical significance and favorable safety profile, positioning it as potential standard-of-care.
Cogent has delivered exceptionally strong clinical results for bezuclastinib in their SUMMIT trial for NonAdvanced Systemic Mastocytosis (NonAdvSM). The data shows clear statistical significance (p=0.0002) in the primary endpoint of Total Symptom Score reduction, with bezuclastinib-treated patients experiencing a 24.3-point reduction versus 15.4 points for placebo 鈥� a meaningful 8.91-point treatment benefit.
What's particularly impressive is the 87.4% of patients achieving 鈮�50% reduction in serum tryptase levels compared to 0% in the placebo arm (p<0.0001). This biomarker reduction strongly validates bezuclastinib's mechanism of action in targeting the underlying disease pathology.
The safety profile appears quite manageable, with most adverse events being low-grade. The most common side effects were hair color change (69.5%), taste alterations (23.7%), nausea (22.0%), and liver enzyme elevations (22.0%). The discontinuation rate of 5.9% due to ALT/AST elevations is reasonable, particularly as all cases fully resolved. Importantly, serious adverse events were actually lower in the treatment arm (4.2%) than placebo (5.0%).
With two additional pivotal readouts expected in 2H 2025 (PEAK for GIST and APEX for AdvSM), Cogent is positioned for potential multi-indication approvals. The company appears on track to submit their first NDA by year-end, suggesting a possible 2026 commercial launch timeline for bezuclastinib, which could become the new standard-of-care in NonAdvSM based on these compelling results.
Cogent strengthens financial position with $230M offering and $400M debt facility, securing runway through FDA approval and into 2027.
Cogent has substantially strengthened its balance sheet through two strategic financial transactions. The company raised $215.8 million in net proceeds from an upsized public offering in July 2025, selling 25.5 million shares at $9.00 per share. Additionally, they secured a substantial $400 million debt facility with SLR Capital Partners, with $50 million already drawn and additional tranches available upon achieving clinical and commercial milestones.
These transactions provide Cogent with $453 million in pro-forma cash, which management projects will fund operations into 2027, covering their anticipated bezuclastinib launch. This extended runway reduces near-term financing risk and provides flexibility through a critical commercialization period.
The company's R&D expenses increased to $62.2 million for Q2 2025 from $54.3 million in Q2 2024, reflecting their advancing clinical programs. G&A expenses rose to $13.4 million from $10.1 million year-over-year, indicating organizational growth in preparation for potential commercialization. The net loss expanded to $73.5 million compared to $59.0 million in the prior year period.
With positive SUMMIT trial results and two additional pivotal readouts expected in 2H 2025, Cogent's financial positioning appears well-timed. The capital infusion provides resources to potentially file their first NDA by year-end and prepare for commercial launch in 2026, while maintaining operational flexibility through these critical value-creating milestones.
Reported positive top-line results from SUMMIT evaluating bezuclastinib in patients with NonAdvanced Systemic Mastocytosis, achieving statistical significance across all primary and key secondary endpoints
On track to share pivotal trial results from PEAK in GIST and APEX in AdvSM in 2H 2025
WALTHAM, Mass. and BOULDER, Colo., Aug. 05, 2025 (GLOBE NEWSWIRE) -- 听(狈补蝉诲补辩: COGT), a biotechnology company focused on developing precision therapies for genetically defined diseases, today reported financial results for the second quarter ended听June 30, 2025.
鈥淲e were thrilled to announce bezuclastinib鈥檚 impressive performance in the SUMMIT trial, demonstrating clinically meaningful and statistically significant results across all primary and key secondary endpoints,鈥� said Andrew Robbins, the Company鈥檚 President and Chief Executive Officer. 鈥淭hese positive data along with the favorable safety profile give us confidence that bezuclastinib has the potential to become the new standard-of-care for NonAdvSM patients. Supported by our recent upsized public offering, Cogent is advancing our mission from a position of strength as we prepare to report top-line results from two additional pivotal trials in GIST and AdvSM in the second half of this year, submit our first New Drug Application by the end of 2025 and make continued progress toward the anticipated commercial launch of bezuclastinib in 2026.鈥�
Recent Business Highlights
- Announced positive top-line results from the registration-directed Part 2 of the SUMMIT clinical trial in NonAdvanced Systemic Mastocytosis (NonAdvSM) patients.
- The SUMMIT trial, which was designed to assess the clinical benefit of bezuclastinib versus placebo, achieved its primary endpoint with a highly statistically significant difference in the mean change in Total Symptom Score (TSS) at 24 weeks (p=0.0002). TSS was assessed by the Mastocytosis Symptom Severity Daily Diary (MS2D2). The bezuclastinib arm had a mean reduction of 24.3 points in TSS at 24 weeks, versus the placebo arm which had a mean reduction of 15.4 points in TSS, resulting in a placebo-adjusted TSS improvement of 8.91 points. In addition, the SUMMIT trial demonstrated highly statistically significant benefit across all key secondary endpoints, including reduction of serum tryptase on which
87.4% of bezuclastinib-treated patients had 鈮�50% reduction, compared to no patients in the control arm (87.4% vs.0% ; p<0.0001). - Bezuclastinib demonstrated a favorable safety and tolerability profile in SUMMIT.
- The majority of treatment emergent adverse events (TEAEs) (
98.3% in bezuclastinib arm vs.88.3% in placebo arm) were of low grade. The most frequent TEAEs reported on bezuclastinib treatment were hair color change (69.5% bezuclastinib vs.5.0% placebo), altered taste (23.7% bezuclastinib vs.0% placebo), nausea (22.0% bezuclastinib vs.13.3% placebo) and ALT/AST elevations (22.0% bezuclastinib vs.6.6% placebo; >Gr 3,5.9% vs.0% ). Serious AEs occurred in4.2% of patients treated with bezuclastinib, compared to5.0% of patients treated with placebo. Discontinuations due to treatment-related AEs occurred in5.9% of patients treated with bezuclastinib, all due to ALT/AST elevations and all patients fully resolved. There were no hepatic AEs reported in any patient other than transient and manageable lab abnormalities.
- The majority of treatment emergent adverse events (TEAEs) (
- The SUMMIT trial, which was designed to assess the clinical benefit of bezuclastinib versus placebo, achieved its primary endpoint with a highly statistically significant difference in the mean change in Total Symptom Score (TSS) at 24 weeks (p=0.0002). TSS was assessed by the Mastocytosis Symptom Severity Daily Diary (MS2D2). The bezuclastinib arm had a mean reduction of 24.3 points in TSS at 24 weeks, versus the placebo arm which had a mean reduction of 15.4 points in TSS, resulting in a placebo-adjusted TSS improvement of 8.91 points. In addition, the SUMMIT trial demonstrated highly statistically significant benefit across all key secondary endpoints, including reduction of serum tryptase on which
- Announced two financial transactions, positioning Cogent with access to over
$800 million in capital.- In June, secured a debt financing facility of up to
$400 million with SLR Capital Partners. An initial tranche of$50 million was drawn at closing in June 2025, with additional tranches available upon achieving key clinical and commercial milestones. - In July, successfully closed an upsized underwritten public offering of 25,555,556 shares of common stock at
$9.00 per share, including the full exercise of the underwriters鈥� option to purchase an additional 3,333,333 shares. This offering generated net proceeds of$215.8 million .
- In June, secured a debt financing facility of up to
Anticipated Upcoming Milestones
- Announce top-line results from PEAK in the second half of 2025. PEAK is a global, blinded, randomized Phase 3 clinical trial studying the combination of bezuclastinib and sunitinib versus sunitinib alone in patients with imatinib-resistant gastrointestinal stromal tumors (GIST).
- Announce top-line results from APEX in the second half of 2025. APEX is a registration-directed, global, open-label trial in patients with advanced systemic mastocytosis (AdvSM).
- Submit Cogent鈥檚 first NDA for bezuclastinib by the end of 2025.
Second Quarter 2025 Financial Results
Cash Position:听As of听June 30, 2025, Cogent had cash, cash equivalents and marketable securities of
R&D Expenses:听Research and development expenses were
G&A Expenses:听General and administrative expenses were
Net Loss:听Net loss was
Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Cogent also announced today that, on July 30, 2025, the Compensation Committee of Cogent鈥檚 Board of Directors, made up entirely of independent directors, approved the grants of 鈥渋nducement鈥� equity awards to six new employees under the company鈥檚 2020 Inducement Plan with a grant date of August 4, 2025. The awards were approved in accordance with Listing Rule 5635(c)(4) of the corporate governance rules of the Nasdaq Stock Market. The employees received, in the aggregate, nonqualified options to purchase 172,450 shares of Cogent common stock. Each option has a 10-year term, an exercise price equal to the closing price of Cogent鈥檚 common stock on the grant date, and a four-year vesting schedule with
About Cogent Biosciences, Inc.
Cogent Biosciences is a biotechnology company focused on developing precision therapies for genetically defined diseases. The most advanced clinical program, bezuclastinib, is a selective tyrosine kinase inhibitor that is designed to potently inhibit the KIT D816V mutation as well as other mutations in KIT exon 17. KIT D816V is responsible for driving systemic mastocytosis, a serious disease caused by unchecked proliferation of mast cells. Exon 17 mutations are also found in patients with advanced gastrointestinal stromal tumors (GIST), a type of cancer with strong dependence on oncogenic KIT signaling. The company also has an ongoing Phase 1 study of its novel internally discovered FGFR2/3 inhibitor. In addition, the Cogent Research Team is developing a portfolio of novel targeted therapies to help patients fighting serious, genetically driven diseases targeting mutations in ErbB2, PI3K伪 and KRAS. Cogent Biosciences is based in Waltham, MA and Boulder, CO. Visit our website for more information at听. Follow Cogent Biosciences on social media:听听(formerly known as Twitter)听and听. Information that may be important to investors will be routinely posted on our website and听.听
Forward Looking Statements
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, including, but not limited to, statements regarding: the company鈥檚 expectation to report top-line results from both PEAK and APEX in the second half of 2025; the potential for bezuclastinib to become the new standard of care for NonAdvSM patients; the company鈥檚 expectation to submit its first NDA by the end of 2025; the anticipated commercial launch of bezuclastinib in 2026; and the company鈥檚 anticipated cash runway into 2027, including through potential FDA approval of bezuclastinib for NonAdvSM and early commercial launch activities. The use of words such as, but not limited to, "anticipate," "believe," "continue," "could," "estimate," "expect," "intend," "may," "might," "plan," "potential," "predict," "project," "should," "target," "will," or "would" and similar words or expressions are intended to identify forward-looking statements. Forward-looking statements are neither historical facts nor assurances of future performance. Instead, they are based on our current beliefs, expectations and assumptions regarding the future of our business, future plans and strategies, our clinical results, the rate of enrollment in our clinical trials and other future conditions. New risks and uncertainties may emerge from time to time, and it is not possible to predict all risks and uncertainties. No representations or warranties (expressed or implied) are made about the accuracy of any such forward-looking statements. We may not actually achieve the forecasts or milestones disclosed in our forward-looking statements, and you should not place undue reliance on our forward-looking statements. Such forward-looking statements are subject to a number of material risks and uncertainties including but not limited to those set forth under the caption "Risk Factors" in Cogent's most recent Annual Report on Form 10-K filed with the SEC, as well as discussions of potential risks, uncertainties, and other important factors in our subsequent filings with the SEC. Any forward-looking statement speaks only as of the date on which it was made. Neither we, nor our affiliates, advisors or representatives, undertake any obligation to publicly update or revise any forward-looking statement, whether as result of new information, future events or otherwise, except as required by law. These forward-looking statements should not be relied upon as representing our views as of any date subsequent to the date hereof.
| COGENT BIOSCIENCES, INC. CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS (in thousands) (unaudited) | |||||||||||||||
| 听 | |||||||||||||||
| 听 | Three Months Ended June 30, | 听 | Six Months Ended June 30, | ||||||||||||
| 听 | 听 | 2025 | 听 | 听 | 听 | 2024 | 听 | 听 | 听 | 2025 | 听 | 听 | 听 | 2024 | 听 |
| Operating expenses: | 听 | 听 | 听 | 听 | 听 | 听 | 听 | ||||||||
| Research and development | $ | 62,203 | 听 | 听 | $ | 54,294 | 听 | 听 | $ | 125,232 | 听 | 听 | $ | 106,999 | 听 |
| General and administrative | 听 | 13,378 | 听 | 听 | 听 | 10,093 | 听 | 听 | 听 | 25,283 | 听 | 听 | 听 | 19,792 | 听 |
| Total operating expenses | 听 | 75,581 | 听 | 听 | 听 | 64,387 | 听 | 听 | 听 | 150,515 | 听 | 听 | 听 | 126,791 | 听 |
| Loss from operations | 听 | (75,581 | ) | 听 | 听 | (64,387 | ) | 听 | 听 | (150,515 | ) | 听 | 听 | (126,791 | ) |
| Other income: | 听 | 听 | 听 | 听 | 听 | 听 | 听 | ||||||||
| Interest income | 听 | 2,373 | 听 | 听 | 听 | 5,393 | 听 | 听 | 听 | 听听听听听听听听听 5,325 | 听 | 听 | 听 | 听听听听听听听听听听听听听听听听 9,450 | 听 |
| Interest expense | 听 | (314 | ) | 听 | 听 | 鈥� | 听 | 听 | 听 | (314 | ) | 听 | 听 | 鈥� | 听 |
| Other income (expense), net | 听 | (6 | ) | 听 | 听 | 44 | 听 | 听 | 听 | (11 | ) | 听 | 听 | 43 | 听 |
| Total other income, net | 听 | 2,053 | 听 | 听 | 听 | 听听听听听听听 听听 5,437 | 听 | 听 | 听 | 听听听听听听听 5,000 | 听 | 听 | 听 | 听听听听听听听听听听听听听听听听听 9,493 | 听 |
| Net loss | $ | (73,529 | ) | 听 | $ | (58,950 | ) | 听 | $ | (145,515 | ) | 听 | $ | (117,298 | ) |
| COGENT BIOSCIENCES, INC. SELECTED CONDENSED CONSOLIDATED BALANCE SHEET DATA (in thousands) (unaudited) | ||||||
| 听 | 听 | 听 | 听 | 听 | ||
| 听 | 听 | June 30, | 听 | December 31, | ||
| 听 | 听 | 听2025 | 听 | 听2024 | ||
| Cash, cash equivalents and marketable securities | 听 | $ | 237,848 | 听 | $ | 287,077 |
| Working capital | 听 | $ | 186,586 | 听 | $ | 240,762 |
| Total assets | 听 | $ | 274,817 | 听 | $ | 327,898 |
| Total liabilities | 听 | $ | 119,781 | 听 | $ | 71,612 |
| Total stockholders鈥� equity | 听 | $ | 155,036 | 听 | $ | 256,286 |
Contact:
Christi Waarich
Sr. Director, Investor Relations
617-830-1653
FAQ
What were the key results from Cogent's SUMMIT trial for bezuclastinib?
How much cash does Cogent Biosciences (COGT) have after recent financing?
What are the main side effects of bezuclastinib reported in the SUMMIT trial?
When will Cogent report results from PEAK and APEX trials?
What is Cogent's timeline for bezuclastinib FDA submission and launch?
